LLMpediaThe first transparent, open encyclopedia generated by LLMs

Ginkgo Bioworks

Generated by DeepSeek V3.2
⚠Note: This article was automatically generated by a large language model (LLM) from purely parametric knowledge (no retrieval). It may contain inaccuracies or hallucinations. This encyclopedia is part of a research project currently under review.
Article Genealogy
Parent: MIT $100K Entrepreneurship Competition Hop 3
Expansion Funnel Raw 61 → Dedup 29 → NER 11 → Enqueued 11
1. Extracted61
2. After dedup29 (None)
3. After NER11 (None)
Rejected: 18 (not NE: 18)
4. Enqueued11 (None)
Ginkgo Bioworks
NameGinkgo Bioworks
Foundation0 2009
FoundersTom Knight, Jason Kelly, Reshma Shetty, Barry Canton, Austin Che
LocationBoston, Massachusetts, United States
IndustryBiotechnology, Synthetic biology
Key peopleJason Kelly (CEO)
Websitehttps://www.ginkgobioworks.com/

Ginkgo Bioworks is a leading American biotechnology company specializing in synthetic biology and cell programming. Founded in 2009 by a team of scientists from the Massachusetts Institute of Technology, the company operates a large-scale platform for designing, building, and testing engineered organisms. Its work spans numerous industries, including pharmaceuticals, agriculture, chemicals, and consumer goods, aiming to program cells to produce valuable products. The company went public in 2021 through a merger with a special-purpose acquisition company sponsored by Harry Sloan and Eli Baker.

History

The company was founded in 2009 by Tom Knight, Jason Kelly, Reshma Shetty, Barry Canton, and Austin Che, all of whom were researchers affiliated with the Massachusetts Institute of Technology and the field of synthetic biology. Initial funding was secured from sources like the Defense Advanced Research Projects Agency and venture capital firms. The company established its headquarters in the Boston Seaport District, later expanding its footprint with large-scale fermentation facilities. A significant milestone was its 2021 merger with the special-purpose acquisition company Soaring Eagle Acquisition Corp., which was backed by notable figures in Hollywood and finance, facilitating its listing on the New York Stock Exchange.

Business model and operations

The company operates on a platform model, offering cell programming services to partners across various sectors rather than developing its own end-product brands. This "foundry" approach provides partners with access to automated biofoundry infrastructure, proprietary machine learning software, and extensive libraries of biological data. Revenue is generated through upfront platform fees, milestone payments, and downstream royalties on products commercialized by partners. Major operational sites include the Boston headquarters and large-scale production facilities, such as those acquired from Bayer in West Sacramento, California.

Technology and platform

The core of the company's offering is its integrated platform for organism design, which combines automation, machine learning, and a massive genetic code library. The platform utilizes advanced robotics and DNA synthesis technologies to automate the process of building and testing genetic designs. A key component is its machine learning and data analytics software, which analyzes performance data from millions of experiments to inform new designs. The company also maintains one of the world's largest collections of enzymes, metabolic pathways, and microbial strains, which serves as a foundational asset for its engineering projects.

Applications and products

Applications of the platform are diverse, spanning multiple industries. In pharmaceuticals and biotechnology, projects include engineering microbes for biomanufacturing novel therapeutics, such as mRNA vaccines and antibiotics, and developing new cell and gene therapy platforms. Within agriculture, work focuses on creating microbial products to enhance crop yield and reduce dependence on synthetic fertilizers. For the chemical industry, the platform is used to develop sustainable production methods for ingredients used in flavors and fragrances, cosmetics, and industrial materials, partnering with companies like Robertet and Boehringer Ingelheim.

Partnerships and collaborations

The company has established a broad network of strategic partnerships with major corporations, government agencies, and research institutions. Notable commercial partners include Pfizer, Moderna, and Corteva in life sciences, and Boehringer Ingelheim in animal health. It has also engaged in significant government contracts, such as those with the United States Department of Defense and the Biomedical Advanced Research and Development Authority for biosecurity and public health initiatives. Research collaborations extend to academic institutions and consortia, including work with the Lawrence Berkeley National Laboratory on the DOE Joint Genome Institute.

Financials and funding

The company has raised substantial capital through multiple funding rounds from prominent investors, including Viking Global Investors, Cascade Investment, and General Atlantic. Its 2021 debut on the New York Stock Exchange via a merger with a special-purpose acquisition company was one of the largest in the biotech sector at the time. Financial reporting shows significant revenue from its platform services, though the company has historically operated at a net loss as it invests heavily in scaling its infrastructure and research and development. Its financial strategy focuses on leveraging its cash reserves to expand its platform capabilities and partner portfolio.

Category:Biotechnology companies of the United States Category:Companies based in Boston Category:Synthetic biology companies Category:Companies listed on the New York Stock Exchange